Cancer Genetics Launches Focused Genomic Panel for Hereditary Breast and Ovarian Cancer Syndrome

Cancer Genetics Launches Focused Genomic Panel for Hereditary Breast and Ovarian Cancer Syndrome
Cancer Genetics has launched Focus:: HERSite, a focused genomic panel for hereditary breast and ovarian cancer syndrome (HBOC). The genomic panel will examine the 16 most common genes associated with breast and ovarian cancers, and provide broad coverage of BRCA1 and BRCA2. “The demand for high quality, clinically validated hereditary cancer testing continues to rise. Over the past year we have seen significant demand from our customer base, both clinical and biopharma, to provide hereditary cancer testing,” said Panna Sharma, Cancer Genetics president and CEO, in a press release. That announcement also estimated the market for hereditary breast and ovarian cancer testing is $2.5 billion, with an annual estimated growth of 7%. “The market is demanding that hereditary cancer testing be both more widely available, and more integrated into one’s comprehensive health profile. We believe that our entry into comprehensive hereditary cancer testing will generate significant additional revenue for CGI during 2017 and beyond,” Sharma added. The Centers for Disease Control and Prevention (CDC) estimate that more than half of the BRCA1 and BRCA2 mutations in women eventually lead to breast cancer by the age of 70. For ovarian cancer, the statistics predict 30% will develop the disease by the same age. “Managing cancer risk by combining our rigorously validated panel of hereditary cancer tests, like Focus::HERSite, with the insig
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *